SecBot SecBot
SECBOTREPLAY Home › Report › INSM

INSM · Insmed reported Q2 2026 revenue of $425.5M, crushing consensus…

INSMED Inc · 8-K filed Aug 6, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

8-K filed Aug 6, 2026 at 07:00 ET

Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49% sequential surge in BRINSUPRI sales to $309.2M. The company raised its full-year BRINSUPRI guidance to $1.25B-$1.4B (from 'at least $1B') and boosted its peak revenue estimate for three lead programs to over $14B. The net loss narrowed dramatically to $13.2M ($0.06/share) from $321.7M ($1.70/share) a year ago, signaling a rapid path to profitability.

  • Q2 2026 total revenue of $425.5M, up 296% YoY vs $107.4M.
  • BRINSUPRI revenue of $309.2M, up 49% sequentially from Q1 2026.
  • Full-year 2026 BRINSUPRI guidance raised to $1.25B-$1.40B from 'at least $1B'.
  • Peak revenue estimate raised to >$14B combined for BRINSUPRI, TPIP, and ARIKAYCE.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access